Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes - Saunthararajah, Yogen; Sekeres, Mikkael; Advani, Anjali; Mahfouz, Reda; Durkin, Lisa; Radivoyevitch, Tomas; Englehaupt, Ricki; Juersivich, Joy; Cooper, Kathleen; Husseinzadeh, Holleh; Przychodzen, Bartlomiej; Rump, Matthew; et al. (The Journal of clinical investigation, 2015)
Keywords: Aged; Aged, 80 and over; Analysis; Antimetabolites, Antineoplastic - administration & dosage; Apoptosis; Azacitidine - administration & dosage; Azacitidine - analogs & derivatives; Biomedical research; Cancer; Cancer therapies; Care and treatment; Clinical Medicine; Clinical trials; Cytotoxicity; Decitabine; Deoxyribonucleic acid; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors; DNA (Cytosine-5-)-Methyltransferases - metabolism; Drug Administration Schedule; Drug dosages; Enzymes; Female; Gene expression; Humans; Hypotheses; Leukemia; Male; Middle Aged; Mortality; Mutation; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - mortality; Oncology, Experimental; Response rates; Stem cells; Studies; Survival Analysis; Transcription factors; Treatment Outcome